Press release content from Business Wire. The AP news staff was not involved in its creation.
Cagent Vascular Announces PRELUDE-BTK Study Results Presented at LINC Symposium: Confirms Serranator Device Novel Mechanism of Action
February 1, 2021 GMT
WAYNE, Pa. (BUSINESS WIRE) Feb 1, 2021
Cagent Vascular, a developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its PRELUDE-BTK Study at this year’s LINC Symposium on January 29th. The PRELUDE-BTK Study, was a prospective, single-arm, multi-center feasibility study to show the safety and efficacy of Serration Angioplasty. The study was led by co-Principal Investigators, Drs. Andrew Holden (Auckland, New Zealand), who presented the data, and Michael Lichtenberg (Arnsberg, Germany). Four other centers from Europe participated in the trial which included 30-day and 6-month follow up.